The sales force is making the best of a bad situation with Nascobal. The fingers need to be pointed at upper mgmt as to why we paid $56 million for a drug that is going to max out at $18-$20 mil a year. That would be a great number if we had a sales force of 50. Problem is that Nascobal is very limited due to cost and coverage in over 65. We are getting friends and family on the drug just to make numbers. Pulling out all the stops for a few redemptions.
Maybe they cut NG for the Nascobal deal, who knows. We need to get back to focusing on our bread and butter, Megace ES, and blow Oravig out of the water. If we don't I am pretty sure PL and the Board will be cutting ties as quickly as they can.
Fair statement on nascobal. Oravig sales will determine extent of sales cuts going forward. No more excuses!
Latest is an upcoming Strativa IPO
Strativa will use the IPO proceeds to fund new branded initiatives going forward and par will scrap shelf offerring as ipo monies will be sufficient so strativa can stand on its own
THIS WILL ALSO UNLOCK VALUE IN PRX SHARES AS THEY REMAIN UNDERVALUED
more later
So it has been 10 months since you posted this, any idea when it is going to happen?
not too far off later this year into early 2011 if all goes as hoped for
what price are you looking at?
Not only are they not cutting bait, they are adding reps
This despite meagace falling off. And we know the megace/nascobal teams are hardly overburdened.
This is 2010 where we do more with less and you know unskilled drug reps are a dime a dozen. blah blah blah
Because your comment is stupid. 4 products sold by 200 reps is far from too many. Get over it.
Because your comment is stupid. 4 products sold by 200 reps is far from too many. Get over it.
200 reps are far too many when as of Sept 1 those 4 drugs will be doing less than $100 million in sales a year.
Megace ES $70 million
Nascobal $20 million
Oravig $5 million in 2010
Zuplenz - May not even launch in 2010
Do the math:
200 reps plus 22 DMs + 3 RBDs = 225 people annual pay = $100k on average (that's probably a low average) = $22,500,000 a year just in salaries. Add in cars, insurance, expense budgets, marketing costs and the compensation of upper mgmt and you see how we currently just about break even.
Unfortunately, if people like yourself are doing the forecasting, we are all screwed and going down in a heap of flames.
Jackass.
200 reps are far too many when as of Sept 1 those 4 drugs will be doing less than $100 million in sales a year.
Megace ES $70 million
Nascobal $20 million
Oravig $5 million in 2010
Zuplenz - May not even launch in 2010
Do the math:
200 reps plus 22 DMs + 3 RBDs = 225 people annual pay = $100k on average (that's probably a low average) = $22,500,000 a year just in salaries. Add in cars, insurance, expense budgets, marketing costs and the compensation of upper mgmt and you see how we currently just about break even.
Unfortunately, if people like yourself are doing the forecasting, we are all screwed and going down in a heap of flames.
Jackass.
Agreed, there are way too many reps for these products. There should have never been an expansion in the first place. They seem to think that more reps equal more sales. Look at other pharma companies. They continue to cut and get by with less. BOD will not happy about expanding on products that can not be justified. Big Pharma has the money to forcast they see that more reps do not equal more dollars.
you know we better kick ass and blow away sales goals or ........
fully agree too many reps at high pay rate with two week shutdown at christmas and too many managers
most reps are hard working but this is too much and the red ink at strativa is never ending
generics division has been supporting strativa since its inception
argument that strativa pays some indirect costs is pure BS
Agreed, there are way too many reps for these products. There should have never been an expansion in the first place. They seem to think that more reps equal more sales. Look at other pharma companies. They continue to cut and get by with less. BOD will not happy about expanding on products that can not be justified. Big Pharma has the money to forcast they see that more reps do not equal more dollars.
Agreed, there are way too many reps for these products. There should have never been an expansion in the first place. They seem to think that more reps equal more sales. Look at other pharma companies. They continue to cut and get by with less. BOD will not happy about expanding on products that can not be justified. Big Pharma has the money to forcast they see that more reps do not equal more dollars.
